Physician profile
Peter A Rubin
NPI 1639154727
$6,927.65
in general payments reported to CMS, 2019-2025
30 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $112 · 2021: $968 · 2022: $1,298 · 2023: $1,168 · 2024: $1,558 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,792 · Education: $7.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,792.08 |
| Education | $7.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,096.86 | 2021-2023 | Tepezza |
| Merz North America, INC. | $548.36 | 2019-2024 | Xeomin |
| Amgen INC. | $518.79 | 2024-2025 | Tepezza |
| Ani Pharmaceuticals, INC. | $430.08 | 2024-2025 | Purified Cortrophin Gel |
| Tarsus Pharmaceuticals, INC. | $412.12 | 2024-2025 | Xdemvy |
| Kerecis Limited | $338.52 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Harrow Eye, LLC | $319.73 | 2024 | Iheezo |
| Acera Surgical, INC. | $308.13 | 2023-2024 | Restrata Wound Matrix |
| Alcon Vision LLC | $260.11 | 2021-2023 | Clareon |
| Biotissue Holdings INC. | $254.82 | 2021-2022 | |
| Carl Zeiss Meditec USA, INC. | $200.79 | 2023 | Quatera 700 |
| Oyster Point Pharma, INC. | $181.46 | 2022-2023 | Tyrvaya |
| Allergan, INC. | $156.77 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $151.63 | 2021 | |
| Revance Therapeutics, INC. | $139.51 | 2024 | Daxi |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $139.29 | 2022 | |
| Eyevance Pharmaceuticals LLC | $134.02 | 2022 | |
| Sun Pharmaceutical Industries INC. | $125.01 | 2021 | |
| Bausch & Lomb Americas INC. | $125.00 | 2024 | Vyzulta |
| Abbvie INC. | $124.74 | 2022 | |
| Ocular Therapeutix, INC. | $120.71 | 2023 | Dextenza |
| Regeneron Healthcare Solutions, INC. | $118.74 | 2024 | Eylea Hd |
| Galderma Laboratories, L.P. | $107.64 | 2019 | |
| Mallinckrodt Hospital Products INC. | $107.29 | 2022 | |
| Novartis Pharmaceuticals Corporation | $103.52 | 2019 | |
| Sight Sciences, INC. | $102.90 | 2019-2021 | |
| Dompe US, INC. | $102.57 | 2021 | |
| Ivantis, INC | $99.20 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.46 | 2023-2024 | Xifaxan |
| Janssen Biotech, INC. | $22.88 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.